ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026. “Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025,” said Timothy Fiori, Chief Financial Officer of ImmuCell. “Our growth in the second quarter is particularly significant given the challenging comparison with the second quarter of 2025, when ImmuCell recorded substantial sales from distributors replenishing inventory following an extended period of backorders. International sales in the three months ended June 30, 2026 declined $0.6 million, or 38.9% compared to 2025; however, we believe that end-customer demand remains strong, particularly in Canada. Total sales for the six months ended June 30, 2026 were $17.5 million, a 20.9% increase compared to the six months ended June 30, 2025.” “We achieved another strong sales quarter, supported by excellent product availability and robust demand in the U.S. for our products,” commented Olivier te Boekhorst, President and CEO. “During the quarter, we directed our commercial efforts toward year-round dairy customers. This more price-sensitive segment generated demand resulting in 23.8% growth of Dual-Force ® and 8.3% growth of Tri-Shield ® . The expansion of our commercial team is contributing to increased customer acquisitions in...